Ambev (NYSE: ABEV) stock: the official figures
Ambev is listed on the New York Stock Exchange under the ticker ABEV and belongs to the consumer staples sector. In fiscal 2025 it reported revenue of BRL 88,243m and a net profit of BRL 15,503m, according to the annual accounts it filed with the regulator.
Identifiers for Ambev: SEC CIK 1565025.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | BRL 88,243m | BRL 89,453m | −1.4% |
| Operating profit | BRL 23,318m | BRL 21,802m | +7.0% |
| Net profit | BRL 15,503m | BRL 14,437m | +7.4% |
| Earnings per share | BRL 0.99 | BRL 0.92 | +8.2% |
| Operating margin | 26.4% | 24.4% | +2.1 pts |
| Net margin | 17.6% | 16.1% | +1.4 pts |
| Total assets | BRL 145,087m | BRL 162,508m | −10.7% |
| Equity | BRL 87,914m | BRL 98,642m | −10.9% |
| Cash | BRL 18,638m | BRL 28,596m | −34.8% |
| Operating cash flow | BRL 24,450m | BRL 26,099m | −6.3% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | BRL 88,243m | BRL 23,318m | BRL 15,503m | BRL 0.99 | Annual report |
| 2024 | BRL 89,453m | BRL 21,802m | BRL 14,437m | BRL 0.92 | Annual report |
| 2023 | BRL 79,737m | BRL 18,831m | BRL 14,502m | BRL 0.92 | Annual report |
| 2022 | BRL 79,709m | BRL 17,688m | BRL 14,458m | BRL 0.92 | Annual report |
| 2021 | BRL 72,854m | BRL 17,080m | BRL 12,671m | BRL 0.81 | Annual report |
| 2020 | BRL 58,379m | BRL 15,972m | BRL 11,379m | BRL 0.72 | Annual report |
| 2019 | BRL 52,005m | BRL 16,075m | BRL 11,780m | BRL 0.75 | Annual report |
| 2018 | BRL 50,231m | BRL 17,151m | BRL 10,995m | BRL 0.70 | Annual report |
| 2017 | BRL 47,899m | BRL 16,552m | BRL 7,269m | BRL 0.47 | Annual report |
| 2016 | BRL 45,603m | BRL 17,105m | BRL 12,547m | BRL 0.80 | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Ambev. Year by year: revenue and net income.
Dividends
In fiscal 2023, Ambev paid BRL 543.9m in dividends, 3.8% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2023 | BRL 543.9m | 3.8% |
| 2022 | BRL 357.4m | 2.5% |
| 2021 | BRL 2,649m | 20.9% |
| 2020 | BRL 1,689m | 14.8% |
| 2019 | BRL 396.0m | 3.4% |
| 2018 | BRL 2,763m | 25.1% |
| 2017 | BRL 4,044m | 55.6% |
| 2016 | BRL 6,007m | 47.9% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Members of Congress who traded Ambev
In the congressional reports read up to 9 November 2026, 1 member has disclosed 4 transactions in Ambev: Josh Gottheimer (4).
Frequently asked questions about Ambev
- How much did Ambev earn in fiscal 2025?
- Ambev reported a net profit of BRL 15,503m for fiscal 2025, on revenue of BRL 88,243m. The year before it reported a net profit of BRL 14,437m.
- What are the earnings per share of Ambev?
- They were BRL 0.99 in fiscal 2025, compared with BRL 0.92 the year before.
- Where is Ambev listed?
- Ambev is listed on the New York Stock Exchange under the ticker ABEV and belongs to the consumer staples sector.
- Where do the figures for Ambev come from?
- From the annual report (Form 20-F) that Ambev files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 20-F) that Ambev files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.